Thank you for donating!

You can donate using the following services.

Need support today?

Main menu

News

  1. 11.02.22

    Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States

    Read more

  2. 03.02.22

    Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C

    Read more

  3. 01.02.22

    Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO

    Read more

  4. 07.12.21

    Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

    Read more

  5. 07.12.21

    EMA accepts regulatory submission for olipudase alfa, the first potential therapy for ASMD

    Read more

2023 Niemann-Pick UK (NPUK). Registered Charity: England and Wales (1144406) / Scotland (SCO45407). Registered as a company limited by guarantee in England and Wales (07775835).

Donate today